Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H19NS |
| Molecular Weight | 293.426 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCC(CC1)=C2C3=C(SC4=C2C=CC=C4)C=CC=C3
InChI
InChIKey=NZLVRVYNQYGMAB-UHFFFAOYSA-N
InChI=1S/C19H19NS/c1-20-12-10-14(11-13-20)19-15-6-2-4-8-17(15)21-18-9-5-3-7-16(18)19/h2-9H,10-13H2,1H3
| Molecular Formula | C19H19NS |
| Molecular Weight | 293.426 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
CNS Activity
Sources: https://www.drugs.com/international/pimethixene.html | https://www.ncbi.nlm.nih.gov/pubmed/674966
Curator's Comment: Sedative agent
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL231 |
10.14 null [pKi] | ||
Target ID: CHEMBL211 |
9.38 null [pKi] | ||
Target ID: CHEMBL224 |
10.22 null [pKi] | ||
Target ID: CHEMBL1833 |
10.44 null [pKi] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | CALMIXENE Approved UseIt is recommended to calm dry cough and irritation coughs in children older than 2 years, especially when they occur in the evening or at night |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [ANTIANAPHYLACTIC PROPERTIES OF 9-(N-METHYL-4'-PIPERIDYLIDENE) THIOXANTHENE (BP 400) AND LYSOZYME, COMPARED TO THOSE OF PREDNISONE]. | 1963 |
|
| BP 400 IN BRONCHIAL ASTHMA. | 1963 |
|
| [Clinical trials of a new antiallergic substance, 9-(N-methyl-4-piperidylidene)-thioxasthene (BP 400)]. | 1963 Mar 16 |
|
| [PRELIMINARY FINDINGS ON THE USE OF 9-(METHYL-4'-PIPERIDYLIDENE)-THIOXANTHENE (BP 400) IN THE TREATMENT OF OBSTRUCTIVE RESPIRATORY INSUFFICIENCY]. | 1963 Oct |
|
| [Clinical experience with the application of pimethixene in the premedication of children]. | 1967 Sep |
|
| [On the pharmacology of 9,10-dihydro-10-(1-methyl-4-piperidylidene)-9-anthrol (WA 335), a histamine and serotonin antagonist (author's transl)]. | 1975 Nov |
|
| [New treatment of hyperkinesis in the child: pimethixene]. | 1978 Jul 15 |
|
| LuxR-dependent quorum sensing: computer aided discovery of new inhibitors structurally unrelated to N-acylhomoserine lactones. | 2010 Aug 1 |
|
| BF-1--a novel selective 5-HT2B receptor antagonist blocking neurogenic dural plasma protein extravasation in guinea pigs. | 2015 Mar 15 |
Patents
Sample Use Guides
Children from 24 to 30 months: 2 to 3 dosing cups (graduation at 5 ml) distributed over the day,
Children from 30 months to 5 years: 3 to 4 dosing cups (graduation at 5 ml) distributed over the day,
Children from 5 to 15 years: 5 to 6 dosing cups (graduation at 5 ml) distributed over the day.
The strongest dose will be kept for the evening due to the possibility of drowsiness related with this
medicine
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:56:15 GMT 2023
by
admin
on
Sat Dec 16 17:56:15 GMT 2023
|
| Record UNII |
T46J20J26F
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QR06AX23
Created by
admin on Sat Dec 16 17:56:15 GMT 2023 , Edited by admin on Sat Dec 16 17:56:15 GMT 2023
|
||
|
NCI_THESAURUS |
C29578
Created by
admin on Sat Dec 16 17:56:15 GMT 2023 , Edited by admin on Sat Dec 16 17:56:15 GMT 2023
|
||
|
WHO-ATC |
R06AX23
Created by
admin on Sat Dec 16 17:56:15 GMT 2023 , Edited by admin on Sat Dec 16 17:56:15 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
314-03-4
Created by
admin on Sat Dec 16 17:56:15 GMT 2023 , Edited by admin on Sat Dec 16 17:56:15 GMT 2023
|
PRIMARY | |||
|
T46J20J26F
Created by
admin on Sat Dec 16 17:56:15 GMT 2023 , Edited by admin on Sat Dec 16 17:56:15 GMT 2023
|
PRIMARY | |||
|
PIMETHIXENE
Created by
admin on Sat Dec 16 17:56:15 GMT 2023 , Edited by admin on Sat Dec 16 17:56:15 GMT 2023
|
PRIMARY | |||
|
DB13292
Created by
admin on Sat Dec 16 17:56:15 GMT 2023 , Edited by admin on Sat Dec 16 17:56:15 GMT 2023
|
PRIMARY | |||
|
SUB09840MIG
Created by
admin on Sat Dec 16 17:56:15 GMT 2023 , Edited by admin on Sat Dec 16 17:56:15 GMT 2023
|
PRIMARY | |||
|
1739
Created by
admin on Sat Dec 16 17:56:15 GMT 2023 , Edited by admin on Sat Dec 16 17:56:15 GMT 2023
|
PRIMARY | |||
|
4822
Created by
admin on Sat Dec 16 17:56:15 GMT 2023 , Edited by admin on Sat Dec 16 17:56:15 GMT 2023
|
PRIMARY | |||
|
CHEMBL152408
Created by
admin on Sat Dec 16 17:56:15 GMT 2023 , Edited by admin on Sat Dec 16 17:56:15 GMT 2023
|
PRIMARY | |||
|
100000081932
Created by
admin on Sat Dec 16 17:56:15 GMT 2023 , Edited by admin on Sat Dec 16 17:56:15 GMT 2023
|
PRIMARY | |||
|
206-240-4
Created by
admin on Sat Dec 16 17:56:15 GMT 2023 , Edited by admin on Sat Dec 16 17:56:15 GMT 2023
|
PRIMARY | |||
|
2169
Created by
admin on Sat Dec 16 17:56:15 GMT 2023 , Edited by admin on Sat Dec 16 17:56:15 GMT 2023
|
PRIMARY | |||
|
DTXSID0048476
Created by
admin on Sat Dec 16 17:56:15 GMT 2023 , Edited by admin on Sat Dec 16 17:56:15 GMT 2023
|
PRIMARY | |||
|
C82276
Created by
admin on Sat Dec 16 17:56:15 GMT 2023 , Edited by admin on Sat Dec 16 17:56:15 GMT 2023
|
PRIMARY | |||
|
33712
Created by
admin on Sat Dec 16 17:56:15 GMT 2023 , Edited by admin on Sat Dec 16 17:56:15 GMT 2023
|
PRIMARY | RxNorm | ||
|
757828
Created by
admin on Sat Dec 16 17:56:15 GMT 2023 , Edited by admin on Sat Dec 16 17:56:15 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
